 |
| Research article summary (published 27 Feb 2002): |
A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia.
Full Abstract
BACKGROUND:
Despite the beneficial effects of atypical antipsychotics on cognition, these improvements will not return most schizophrenic patients to normative standards of cognitive functioning. Therefore, other treatments need to be considered. Subtle changes in cholinergic function in schizophrenic patients provide the rationale to test the effectiveness of cholinesterase inhibitors in treating cognitive impairment in schizophrenia.
METHODS:
Given this, a 12-week, double-blind, placebo-controlled trial of donepezil (5 mg and 10 mg) as adjunctive treatment to risperidone was conducted in a total of 36 schizophrenic patients.
RESULTS:
Neither the 5-mg nor 10-mg dose of donepezil produced significant improvements in any cognitive measure compared with placebo.
CONCLUSIONS:
It is possible that nicotinic receptor desensitization produced by chronic tobacco use in these patients rendered their nicotinic receptors refractory to the effects of increased agonist activity produced by donepezil. An alternative treatment is the allosterically potentiating ligands, which enhance the activity of (sensitize) nicotinic receptors in the presence of acetylcholine.
Learn Faster Today Improve your study skills
Author information
Author/s: Friedman, Joseph I (JI); Adler, David N (DN); Howanitz, Evelyn (E); Harvey, Philip D (PD); Brenner, Grant (G); Temporini, Humberto (H); White, Leonard (L); Parrella, Michael (M); Davis, Kenneth L (KL);
Affiliation: Department of Psychiatry, The Mount Sinai School of Medicine, New York, NY 10029, USA.
Journal and publication information
Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal: Biological psychiatry (Biol Psychiatry), published in United States. (Language: eng)
Reference: 2002-Mar; vol 51 (issue 5) : pp 349-57
Dates: Created 2002/03/20; Completed 2002/05/13; Revised 2006/11/15;
PMID: 11904128, status: MEDLINE (last retrieval date: 11/6/2008)
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
Comments and Corrections
CommentIn: Curr Psychiatry Rep. 2003 Oct;5(5):367-8. (PMID: 13678558)
External Links for this article (including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
|
|
Related articles
This article has not been indexed for related articles as yet, however you can still use the live related article search links below.
See a large map of 100+ related articles.